PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2174104-6	1990	A synthetic oligonucleotide corresponding to this binding site, as well as a similar sequence found in another class III complement C4 gene, conferred IL-1 responsiveness on the minimal factor B promoter.	Oligonucleotides	12-27	interleukin 1 complex	Mus musculus	151-155	
10759763-4	2000	When antisense oligonucleotide was given on day 0, the disease activity index (DAI) representing clinical symptoms improved and the histological score decreased; furthermore, IL-1, IL-6, and TNF-alpha concentrations in rectal mucosa were lower compared with the control group.	Oligonucleotides	15-30	interleukin 1 complex	Mus musculus	175-179	
8325323-10	1993	Binding of IL-1 NF to the TCEd site was competed by a typical chi B oligonucleotide, suggesting that it is similar to NF-chi B in its DNA-binding properties.	Oligonucleotides	68-83	interleukin 1 complex	Mus musculus	11-15	
1833422-2	1991	Murine antisense oligonucleotides inhibited IL-1-stimulated PGE2 synthesis by murine fibroblasts in culture in a time (days) and concentration-dependent (3 microM-30 microM) fashion.	Oligonucleotides	17-33	interleukin 1 complex	Mus musculus	44-48	
1833422-5	1991	Similarly, antisense oligonucleotides to the human, but not the murine, IL-1 receptor inhibited IL-1-stimulated PGE2 synthesis by cultured human fibroblasts.	Oligonucleotides	21-37	interleukin 1 complex	Mus musculus	96-100	
1833422-6	1991	The attenuation of the cellular response to IL-1 caused by the antisense oligonucleotides correlated with a loss in cell surface receptors for IL-1, without any change in the number of bradykinin receptors on these cells.	Oligonucleotides	73-89	interleukin 1 complex	Mus musculus	44-48	
1833422-6	1991	The attenuation of the cellular response to IL-1 caused by the antisense oligonucleotides correlated with a loss in cell surface receptors for IL-1, without any change in the number of bradykinin receptors on these cells.	Oligonucleotides	73-89	interleukin 1 complex	Mus musculus	143-147	
1833422-7	1991	When antisense oligonucleotides were encapsulated in liposomes, they blocked completely the appearance of newly synthesized IL-1 receptors and IL-1-stimulated PGE2 synthesis.	Oligonucleotides	15-31	interleukin 1 complex	Mus musculus	124-128	
1833422-7	1991	When antisense oligonucleotides were encapsulated in liposomes, they blocked completely the appearance of newly synthesized IL-1 receptors and IL-1-stimulated PGE2 synthesis.	Oligonucleotides	15-31	interleukin 1 complex	Mus musculus	143-147	
1833422-8	1991	In mice, subcutaneous injection with an oligonucleotide antisense to the murine IL-1 receptor markedly inhibited the infiltration of neutrophils in response to subsequent injection of IL-1.	Oligonucleotides	40-55	interleukin 1 complex	Mus musculus	80-84	
1833422-8	1991	In mice, subcutaneous injection with an oligonucleotide antisense to the murine IL-1 receptor markedly inhibited the infiltration of neutrophils in response to subsequent injection of IL-1.	Oligonucleotides	40-55	interleukin 1 complex	Mus musculus	184-188	
7877456-6	1994	Oligonucleotide probes were then synthesized and used in RT-PCR followed by Southern blotting to show that the whole brain expresses transcripts for both the type I and type II IL-1 receptors.	Oligonucleotides	0-15	interleukin 1 complex	Mus musculus	177-181	
1978316-6	1990	Addition to AtT-20 cells of antisense oligonucleotides to Fos and Jun abolished the secretion induced by IL-1.	Oligonucleotides	38-54	interleukin 1 complex	Mus musculus	105-109